Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Buti

Showing results (261-270 of 387) with videos related to

Pageof 39
Sort By:
Microbiology Spectrum|April 4, 2022
Standardized Hepatitis B Virus RNA Quantification in Untreated and Treated Chronic Patients: a Promising Marker of Infection Follow-UpMaria Francesca Cortese, Mar Riveiro-Barciela, David Tabernero, et al.
Gut|August 19, 2016
Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis BJulianne Bayliss, Lilly Yuen, Gillian Rosenberg, et al.
Microorganisms|May 25, 2024
In-Host Flat-like Quasispecies: Characterization Methods and Clinical ImplicationsJosep Gregori, Sergi Colomer-Castell, Marta Ibañez-Lligoña, et al.
Hepatology (Baltimore, Md.)|January 30, 2019
JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1Stefan Zeuzem, Stefan Bourgeois, Susan Greenbloom, et al.
The Journal of Infectious Diseases|April 23, 2020
Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B StudyMilan J Sonneveld, Bettina E Hansen, Willem P Brouwer, et al.
Alimentary Pharmacology & Therapeutics|June 28, 2021
One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the diseaseAdriana Palom, Sara Sopena, Mar Riveiro-Barciela, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 4, 2014
Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml)Scott Fung, Stuart C Gordon, Zahary Krastev, et al.
Journal of Hepatology|September 9, 2014
Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovirGeorge V Papatheodoridis, George N Dalekos, Cihan Yurdaydin, et al.
Scientific Reports|July 21, 2019
Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patientsOndrej Podlaha, Edward Gane, Maurizia Brunetto, et al.
Antimicrobial Agents and Chemotherapy|July 25, 2018
No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B InfectionAndrea L Cathcart, Henry Lik-Yuen Chan, Neeru Bhardwaj, et al.
Pageof 39

Showing results (261-270 of 387) with videos related to

Sort By:
Pageof 39
Microbiology Spectrum|April 4, 2022
Standardized Hepatitis B Virus RNA Quantification in Untreated and Treated Chronic Patients: a Promising Marker of Infection Follow-UpMaria Francesca Cortese, Mar Riveiro-Barciela, David Tabernero, et al.
Gut|August 19, 2016
Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis BJulianne Bayliss, Lilly Yuen, Gillian Rosenberg, et al.
Microorganisms|May 25, 2024
In-Host Flat-like Quasispecies: Characterization Methods and Clinical ImplicationsJosep Gregori, Sergi Colomer-Castell, Marta Ibañez-Lligoña, et al.
Hepatology (Baltimore, Md.)|January 30, 2019
JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1Stefan Zeuzem, Stefan Bourgeois, Susan Greenbloom, et al.
The Journal of Infectious Diseases|April 23, 2020
Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B StudyMilan J Sonneveld, Bettina E Hansen, Willem P Brouwer, et al.
Alimentary Pharmacology & Therapeutics|June 28, 2021
One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the diseaseAdriana Palom, Sara Sopena, Mar Riveiro-Barciela, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 4, 2014
Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml)Scott Fung, Stuart C Gordon, Zahary Krastev, et al.
Journal of Hepatology|September 9, 2014
Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovirGeorge V Papatheodoridis, George N Dalekos, Cihan Yurdaydin, et al.
Scientific Reports|July 21, 2019
Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patientsOndrej Podlaha, Edward Gane, Maurizia Brunetto, et al.
Antimicrobial Agents and Chemotherapy|July 25, 2018
No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B InfectionAndrea L Cathcart, Henry Lik-Yuen Chan, Neeru Bhardwaj, et al.
Pageof 39